Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $682000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 42.4% to $682000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 7.18% year-over-year, with the annual reading at $3.6 million for FY2025, 7.18% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $682000.0 at Caribou Biosciences, up from $631000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.6 million in Q3 2023, with the low at $221000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $685150.0, with a median of $624000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) surged 250.89% in 2023, then crashed 46.39% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $273000.0 in 2021, then skyrocketed by 85.35% to $506000.0 in 2022, then surged by 46.25% to $740000.0 in 2023, then skyrocketed by 60.0% to $1.2 million in 2024, then tumbled by 42.4% to $682000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $682000.0, $631000.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.